Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 700.97M | 674.98M | 666.82M | 541.53M | 420.83M |
Gross Profit | 530.54M | 490.31M | 467.53M | 401.28M | 303.50M |
EBITDA | 32.25M | 157.58M | 144.78M | 118.47M | 71.42M |
Net Income | -99.56M | 41.95M | 15.91M | 41.98M | 145.52M |
Balance Sheet | |||||
Total Assets | 1.55B | 1.57B | 1.68B | 2.08B | 1.27B |
Cash, Cash Equivalents and Short-Term Investments | 484.62M | 278.58M | 288.65M | 656.41M | 521.66M |
Total Debt | 638.85M | 586.04M | 763.39M | 1.13B | 541.13M |
Total Liabilities | 775.17M | 704.26M | 906.19M | 1.34B | 654.83M |
Stockholders Equity | 778.35M | 870.13M | 775.01M | 730.41M | 619.69M |
Cash Flow | |||||
Free Cash Flow | 178.75M | 139.49M | 115.20M | 79.85M | 39.23M |
Operating Cash Flow | 189.39M | 154.65M | 145.27M | 125.72M | 77.03M |
Investing Cash Flow | -83.28M | 77.54M | -225.19M | -20.79M | -277.61M |
Financing Cash Flow | 17.36M | -183.03M | -401.53M | 380.69M | 222.30M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $1.02B | 26.08 | 19.23% | ― | 17.17% | -51.97% | |
75 Outperform | $1.44B | ― | -5.19% | ― | 30.26% | -173.36% | |
71 Outperform | $1.83B | 29.58 | 6.32% | ― | 11.82% | ― | |
68 Neutral | $1.07B | 8.21 | 19.90% | ― | 8.05% | -8.46% | |
67 Neutral | $1.09B | ― | -34.65% | ― | 252.64% | 85.10% | |
60 Neutral | $1.04B | ― | -12.27% | ― | 3.08% | -247.82% | |
52 Neutral | $7.61B | 0.04 | -62.94% | 2.44% | 16.14% | 0.33% |
On July 9, 2025, Pacira BioSciences, Inc. implemented a workforce reduction at its San Diego Science Center Campus due to improved manufacturing efficiencies for EXPAREL, resulting from investments in large-scale manufacturing suites. This decision led to the decommissioning of a 45-liter manufacturing suite and affected 71 employees, approximately 8% of the workforce. The company anticipates recognizing pre-tax charges of $2.4 million to $2.8 million related to employee termination benefits and expects an annual reduction in operating expenses of approximately $13 million. The move reflects Pacira’s strategic focus on optimizing production capacity and cost structure to support growing demand for its products.
The most recent analyst rating on (PCRX) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.
On July 3, 2025, Pacira BioSciences, Inc. entered into a new credit agreement with Wells Fargo Bank and other lenders to refinance its existing credit agreement and provide ongoing working capital. The agreement includes a $300 million senior secured revolving credit facility, with a maturity date of July 3, 2030, and is secured by the company’s and its subsidiaries’ assets. The company used part of this facility to repay its previous credit agreement without incurring prepayment penalties, potentially enhancing its financial flexibility and operational capacity.
The most recent analyst rating on (PCRX) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.
On June 10, 2025, Pacira BioSciences, Inc. held its Annual Meeting of Stockholders in Parsippany, New Jersey, where stockholders approved the Amended and Restated 2011 Stock Incentive Plan, increasing the number of shares authorized for grant by 2,500,000. Additionally, the meeting included the election of directors, ratification of KPMG LLP as the accounting firm, and decisions on executive compensation, with the board opting for annual advisory votes on executive pay, reflecting a commitment to good corporate governance.
The most recent analyst rating on (PCRX) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.